Recent Updates
Recently added Catalysts

InflaRx N.V.

IFRXFDA catalysts, PDUFA dates & pipeline intelligence
$1.15
▼ -0.03 · -2.54%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IFRX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.8052W HIGH $2.95
Volume
1.99 M
Value Traded
2.29 M
Short % Float
10.22%
Days to Cover
15.0
-2.54%Week
-20.69%1 Month
-45.75%3 Month
-52.87%6 Month
-11.82%5 Year
-82.82%All Time

Cash Data

Unlock IFRX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
169.47 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
143.77 M
Total Shares
147.37 M
Float Shares
125.63 M
Insiders
14.75%
Institutions
62.11%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout
izicopan
ANCA-associated vasculitis (AAV) - randomized, placebo-controlled renal vasculitis study
Phase 2Small MoleculesRare Disease
Unlock every IFRX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IFRX Catalyst Timeline

Dated clinical, regulatory and corporate events for InflaRx N.V.

Catalyst Timeline

Dated clinical, regulatory & corporate events for InflaRx N.V.

488Total events
16Upcoming
110Tier-1 (high impact)
2017 to 2029Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
INF904
T1Topline Readout
Subscribe to view catalyst details
INF904

Event history 50

▲PublicationINF904Presentation
Peer-reviewed publication of izicopan Phase 1 SAD/MAD data
●Poster PresentationINF904Presentation
Poster: 'Izicopan, a second-generation oral C5a receptor 1 (C5aR1) antagonist, demonstrates promising therapeutic potential in kidney disease models'
kidney disease modelssource ↗
▲Preclinical PoCINF904Preclinical
Izicopan reduced creatinine, BUN and histopathological injury in renal IRI model
renal ischemia–reperfusion injury (acute kidney injury)source ↗
●Management ChangeCorporate
Gabriela Alperovich appointed SVP & Global Head of Clinical Development
●Quarterly UpdateCorporate
Reported Q2 2026 financial results
◆Trial InitiationINF904Trial
Phase 2 planning for izicopan in AAV continues
ANCA-associated vasculitis (AAV)source ↗
▲Runway Guidance UpdateCorporate
Cash runway projected through 2029
▼CHMP Negative OpinionTavneosEx-US Regulatory
CHMP recommended to revoke marketing authorization for Tavneos in EU
ANCA-associated vasculitissource ↗
▼CHMP Negative OpinionTavneosEx-US Regulatory
EMA CHMP recommended revocation of marketing authorization for Tavneos in EU
ANCA-associated vasculitissource ↗
▼Equity OfferingCorporate
Closed $150 million underwritten offering of 75,000,000 ordinary shares at $2.00 per share
Unlock the full IFRX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IFRX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-22izicopan Pre-clinical data presentation Pre-clinical
Unlock 7 more IFRX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 36%
Micro Cap
(rank 262 of 725)
Percentile Rank
Showing 2 of 7 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
IFX-1 BiologicsCompletedNCT04333420Severe COVID-19 PneumoniaPhase 2/3 COMPLETED 399Dec 1, 2021
IFX-1 BiologicsCompletedNCT03487276Hidradenitis SuppurativaPhase 2 COMPLETED 191Jan 27, 2020
Unlock the IFRX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IFRX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
izicopan immune-inflammatory diseasesPhase 12026-11-06Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signaling; single doses ranging from 3 mg to 240 mg and at multiple doses of 30 mg once daily, 30 mg twice daily and 90 mg twice daily for 14 days; greater than 90% blockade of C5a-induced CD11b upregulation within two to four hours; strong activity maintained at 24 hours across most of the evaluated dose cohorts; greater than 90% blockade was observed following a single 30 mg dose; blockade exceeded 95% at multiple time points from Day 2 through Day 15; maximum plasma concentrations reached approximately 3.5 to 6 hours after dosingRead MoreInflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of IzicopanRead More
Scroll for more · summaries link to the source press release
Unlock every IFRX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IFRX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full IFRX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
TCG Crossover Management, LLC 0.7 % (-12.5 %) 26.10 M 14.50 M
Unlock every fund holding IFRX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IFRX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IFRX ownership
Insider and institutional ownership, quarter by quarter.

IFRX Short Interest

Shares sold short, counted twice a month.

10.22%
Short % of Float
of tradable shares sold short
12.8M
Shares Sold Short
+0.9% vs prior count
15.0 Very high
Days to Cover
trading days of normal volume to buy every short share back
855.4K
Avg Daily Volume
the average used for days to cover
Unlock IFRX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock IFRX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IFRX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IFRX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IFRX ranks across every disease it competes in

Competitive Position is a premium feature
See how IFRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IFRX News

IFRX
Nov 6, 2026
IFRXPhases

InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan

InflaRx published Phase 1 data for izicopan, demonstrating its safety and pharmacokinetic profile. The study involved 86 healthy participants and showed favorable results, including rapid inhibition of C5a signaling. The findings support advancing izicopan into Phase 2 trials for immune-inflammatory diseases.

Read more →
IFRX
Nov 3, 2026
IFRXPhases
▼ -8.2%on this news· ran to -26% by day 3shared move

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

InflaRx outlined its development strategy for izicopan at its Capital Markets Day, announcing plans for two Phase 2 trials in ANCA-associated vasculitis starting in 2027. The company anticipates significant market potential for izicopan, estimating peak sales between $1.5 billion and $2.0 billion. Initial data from related studies is expected in 2028.

Read more →
IFRX
Oct 27, 2026
IFRXConferences/Events
▲ +5.4%on this news

InflaRx Announces November Investor Events

InflaRx N.V. announced its November investor events calendar, including participation in the Guggenheim Securities Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. The company will report its third quarter 2026 financial results on November 3, 2026, via a Form 6-K with the SEC. Additionally, InflaRx will host a virtual Capital Markets Day on November 3 to discuss its development strategy for izicopan in ANCA-associated vasculitis.

Read more →
IFRX
Oct 22, 2026
IFRXConferences/Events

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

InflaRx presented pre-clinical data on izicopan at Kidney Week 2026, showing renal protection in kidney disease models. Oral izicopan significantly reduced creatinine, blood urea nitrogen, and histopathological scores in hamster models. The company plans to advance the drug for ANCA-associated vasculitis and additional renal indications.

Read more →
IFRX
Oct 2, 2026
IFRXConferences/Events

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

InflaRx N.V. has been selected to present late-breaking pre-clinical data on izicopan at Kidney Week 2026. The poster will highlight izicopan's potential as a second-generation oral C5a receptor antagonist in kidney disease models. The drug has demonstrated a favorable safety profile and significant therapeutic effects in various clinical studies.

Read more →
IFRX
Oct 1, 2026
IFRXGeneral
▼ -5%on this newsshared move

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

InflaRx N.V. has appointed Dr. Gabriela Alperovich as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026. Dr. Alperovich brings over 20 years of experience in the pharmaceutical industry, particularly in immune-inflammatory diseases. Her expertise will be crucial as InflaRx advances its lead program, izicopan, targeting renal and complement-driven diseases.

Read more →
IFRX
Sep 21, 2026
IFRXConferences/Events

InflaRx to Host Virtual Capital Markets Day

InflaRx N.V. will host a virtual Capital Markets Event on November 3, 2026, featuring discussions on ANCA-associated vasculitis and the company's drug izicopan. Key opinion leaders will provide insights into the treatment landscape and the drug's potential advantages. The event aims to update stakeholders on InflaRx's clinical development strategy.

Read more →
IFRX
Aug 20, 2026
IFRXConferences/Events

InflaRx Announces Participation in September Investor Conferences

InflaRx N.V. will participate in two investor conferences in September 2026, including the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference. The company will conduct fireside chats and one-on-one investor meetings at both events. InflaRx is known for its innovative anti-inflammatory therapeutics, particularly its lead program, izicopan.

Read more →
IFRX
Aug 6, 2026
IFRXGeneral

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

InflaRx N.V. reported its second-quarter results for 2026, highlighting significant progress in the development of izicopan for ANCA-associated vasculitis and renal diseases. The company has a solid financial footing with €158.4 million in cash and plans to initiate a PK bridging study in China. A Capital Markets Day is scheduled for October 8, 2026, to discuss future strategies.

Read more →
IFRX
Jul 30, 2026
IFRXGeneral

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

InflaRx N.V. has announced it will report its second quarter 2026 financial results on August 6, 2026, prior to market opening. The company focuses on developing anti-inflammatory therapeutics, with its lead program izicopan showing promising results in clinical studies. No conference call is scheduled for this announcement.

Read more →
IFRX
Jun 30, 2026
IFRXFDA Updates

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx is evaluating a broader strategy for ANCA-associated vasculitis (AAV) in Europe following an EMA recommendation to revoke Tavneos' marketing authorization. The company plans to engage with the EMA regarding its anti-C5a antibody vilobelimab and the oral C5aR inhibitor izicopan. Despite regulatory challenges, Phase 2 planning with izicopan continues as scheduled.

Read more →
IFRX
May 8, 2026
IFRXGeneral

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx N.V. has completed an underwritten offering of 75 million ordinary shares at $2.00 each, raising $150 million. The proceeds will be utilized to further develop its pipeline and for general corporate needs. The offering saw participation from various investors, including prominent healthcare funds. Guggenheim Securities led the offering.

Read more →
IFRX
May 6, 2026
IFRXGeneral
▲ +26.9%on this newsshared move

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx N.V. has announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 each, aiming to raise $150 million. The proceeds will be utilized for advancing pipeline activities and general corporate purposes. The offering is set to close on May 7, 2026, pending customary conditions.

Read more →
IFRX
May 6, 2026
IFRXPhases
▲ +26.9%on this newsshared move

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx N.V. is advancing izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis and other renal diseases. The company plans to conduct Phase 2 studies and aims to establish proof of concept in additional life-threatening kidney disorders. A Capital Markets Day is scheduled for summer 2026 to discuss izicopan's potential. InflaRx has sufficient funding to support its development programs through 2029.

Read more →
IFRX
May 4, 2026
IFRXPhases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx announced favorable pre-clinical data for izicopan, showing low reactive metabolite formation in human liver microsomes. This suggests a lower bioactivation-related safety risk compared to avacopan, a marketed C5aR1 inhibitor. The results support izicopan's potential for improved efficacy and safety in treating inflammatory diseases. The company aims to further validate these findings in clinical studies.

Read more →
IFRX
May 1, 2026
IFRXGeneral

InflaRx to Report First Quarter 2026 Results on May 7, 2026

InflaRx N.V. will release its financial results for Q1 2026 on May 7, 2026, prior to market opening. The company is known for its innovative anti-inflammatory therapeutics targeting the complement system, particularly through its lead program izicopan. No conference call is scheduled for this announcement.

Read more →
IFRX
Apr 28, 2026
IFRXGeneral

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

InflaRx N.V. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company achieved this by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This compliance is crucial for the company's continued listing on Nasdaq and reflects positively on its market performance.

Read more →
IFRX
Apr 23, 2026
IFRXGeneral

This is a translation into English of the deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch

InflaRx N.V. has enacted a deed of amendment to its articles of association, as decided during a general meeting of shareholders in Amsterdam. The amendment involves particular changes to the company's structure and share capital, with a specific focus on adjusting nominal values. The changes are set to take effect upon the issued share capital reaching a stipulated amount. This amendment follows a previous adjustment made in April 2025.

Read more →
IFRX
Apr 9, 2026
IFRXPhases
▲ +8.4%on this news· ran to +20% by day 3

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

InflaRx N.V. has reported new in vitro data indicating that izicopan, an oral C5a receptor inhibitor, does not cause time-dependent inhibition of CYP3A4, which is crucial for assessing drug-drug interactions. This finding supports izicopan's potential as a best-in-class treatment for inflammatory diseases. The drug has demonstrated favorable pharmacokinetic and pharmacodynamic profiles in clinical studies.

Read more →
IFRX
Apr 2, 2026
IFRXGeneral

CONVENING NOTICE This is the convening notice for the 2026 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on

InflaRx N.V. has issued a convening notice for its 2026 annual general meeting scheduled for April 23, 2026, in Amsterdam. The agenda includes the adoption of the annual accounts for 2025, reappointments of key executives, and auditor nomination. The company has also reiterated its policy of not paying dividends in the foreseeable future, focusing instead on retaining funds for business development. Shareholders must follow specific protocols to attend or vote at the AGM.

Read more →

About InflaRx N.V.

65 employees inflarx.de
BIOPHARMAWATCH ELITE
Trade the next IFRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime